Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [31] Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis
    Lin, En-Kwang
    Hsieh, Mao-Chih
    Chen, Chien-Hsin
    Lu, Yen-Jung
    Wu, Szu-Yuan
    MEDICINE, 2016, 95 (52)
  • [32] RESULTS OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY AND CYTOREDUCTIVE SURGERY FOR PERITONEAL CARCINOMATOSIS OF COLORECTAL ORIGIN
    Merayo Alvarez, M.
    Turienzo Santos, E.
    Garcia Munar, M.
    Cifrian Canales, I.
    Rodicio Miravalles, J. L.
    Moreno Gijon, M.
    Sanz Alvarez, L.
    BRITISH JOURNAL OF SURGERY, 2021, 108 : 17 - 17
  • [33] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis
    Nesher, Eviatar
    Greenberg, Ron
    Avital, Shmuel
    Skornick, Yehuda
    Schneebaunn, Schlomo
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (11): : 787 - 790
  • [34] Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Sarcomatosis
    Randle, Reese W.
    Swett, Katrina R.
    Shen, Perry
    Stewart, John H.
    Levine, Edward A.
    Votanopoulos, Konstantinos I.
    AMERICAN SURGEON, 2013, 79 (06) : 620 - 624
  • [35] Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Pantelis, Arnos
    Ben-Yaacov, Almog
    Adileh, Mohammad
    Schtrechman, Gal
    Shacham-Shmueli, Einat
    Boursi, Ben
    Margalit, Ofer
    Halpern, Naama
    Mor, Eyal
    Assaf, Dan
    Maximiliano, Klug
    Nissan, Aviram
    Laks, Shachar
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (08) : 1724 - 1731
  • [36] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
    Khan, Hadi M.
    Hanif, Hamza
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (02): : 259 - 261
  • [37] Peritoneal sarcomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Spiliotis, John
    Kopanakis, Nikolaos
    Prodromidou, Anastasia
    Raptis, Apostolos
    Farmakis, Dimitrios
    Efstathiou, Elias
    SURGICAL INNOVATION, 2021, 28 (03) : 394 - 395
  • [38] Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Arnos Pantelis
    Almog Ben-Yaacov
    Mohammad Adileh
    Gal Schtrechman
    Einat Shacham-Shmueli
    Ben Boursi
    Ofer Margalit
    Naama Halpern
    Eyal Mor
    Dan Assaf
    Klug Maximiliano
    Aviram Nissan
    Shachar Laks
    Journal of Gastrointestinal Surgery, 2022, 26 (8) : 1724 - 1731
  • [39] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience
    Koenigsrainer, Ingmar
    Horvath, Philipp
    Struller, Florian
    Grischke, Eva Maria
    Wallwiener, Diethelm
    Koenigsrainer, Alfred
    Beckert, Stefan
    LANGENBECKS ARCHIVES OF SURGERY, 2014, 399 (05) : 589 - 594
  • [40] Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Peter H. Cashin
    Wilhelm Graf
    Peter Nygren
    Haile Mahteme
    Annals of Surgical Oncology, 2013, 20 : 4183 - 4189